Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia

References

• Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains. Psychopharmacology (Berl) 1990;102:474–8.
   PubMed Web of Science ®Google Scholar
• Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618–9.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12:431–50.
   PubMed Web of Science ®Google Scholar
• Casey DE, Gerlach, Magelund G, Christensen TR. gamma- Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376–9.
   PubMed Web of Science ®Google Scholar
• Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerobrospinal fluid monomaine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509–23.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525–41.
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: Current concepts and future perspectives. Drugs Today 2003;39:19–49.
   PubMedGoogle Scholar
• Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347–9.
   PubMed Web of Science ®Google Scholar
• Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy. Am J Psychiatry 1990; 147:445–51.
   PubMed Web of Science ®Google Scholar
• Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008;18:317–23.
   PubMed Web of Science ®Google Scholar
• Han OS, Hong JP. Structured Clinical Interview for DSM-IV Axis I Disorder–Korean Version. Seoul: Hana Medical Publishing; 2000.
   Google Scholar
• Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007;55:47–51.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein β3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007;22:501–4.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. No evidence for association between tyrosine hydroxylase gene Val81Met polymorphism and susceptibility to tardive dyskinesia in schizophrenia. Psychiatry Investig 2009;6:108–11.
   PubMed Web of Science ®Google Scholar
• Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1545–8.
   PubMed Web of Science ®Google Scholar
• Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1844–7.
   PubMed Web of Science ®Google Scholar
• Kang SG, Choi JE, Park YM, Lee HJ, Han C, Kim YK, et al. Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008;57:22–5.
   PubMed Web of Science ®Google Scholar
• Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009;24:55–60.
   PubMed Web of Science ®Google Scholar
• Park YM, Kang SG, Choi JE, Kim YK, Kim SH, Park JY, et al. No evidence for an association between dopamine D2 receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig 2011;8:49–54.
   PubMed Web of Science ®Google Scholar
• Kim IS, Yoon HK, Kang SG, Park YM, Kim YK, Kim SH, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients. Psychiatry Investig 2012;9:191–4.
   PubMed Web of Science ®Google Scholar
• Guy W. Abnormal Involuntary Movement Scale (AIMS); ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare; 1976. p. 534–537.
   Google Scholar
• Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486–7.
   PubMed Web of Science ®Google Scholar
• Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009;41:1149–60.
   PubMed Web of Science ®Google Scholar
• Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene–gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003;24:150–7.
   PubMed Web of Science ®Google Scholar
• Motsinger AA, Ritchie MD. The effect of reduction in crossvalidation intervals on the performance of multifactor dimensionality reduction. Genet Epidemiol 2006;30:546–55.
   PubMed Web of Science ®Google Scholar
• Chung Y, Lee SY, Elston RC, Park T. Odds ratio based multifactor-dimensionality reduction method for detecting gene–gene interactions. Bioinformatics 2007;23:71–6.
   PubMedGoogle Scholar
• Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 1995;133:175–88.
   PubMedGoogle Scholar
• Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010;153B:336–40.
   PubMed Web of Science ®Google Scholar
• Han GR, Lee YW, Lee HL, Kim SM, Ku TW, Kang IH, et al. A Korean population study of the nine STR loci FGA, VWA, D3S1358, D18S51, D21S11, D8S1179, D7S820, D13S317 and D5S818. Int J Legal Med 2000;114:41–4.
   PubMed Web of Science ®Google Scholar